Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination formulation of aripiprazole (an atypical antipsychotic) and sertraline (a selective serotonin reuptake inhibitor) developed for the treatment of major depressive disorder and bipolar depression. It combines serotonin reuptake inhibition from sertraline with modulation of dopamine and serotonin receptors from aripiprazole.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aripiprazole + sertraline.